Short-Term Debt to Equity Ratio: Denali Therapeutics (DNLI)
The market price visualization for the DNLI ticker on the GURU.Markets platform demonstrates the 0.02 indicator. Denali Therapeutics brings together leading neurobiologists to create a research environment dedicated to combating degenerative brain pathologies. The company is developing innovative methods to cross the blood-brain barrier, providing it with a patent advantage and strategic interest from pharmaceutical behemoths in the therapy of Parkinson's and Alzheimer's diseases.
denalitherapeutics.com (DNLI) - metric breakdowns and financial figures
- stock quotes and analyst forecast:
- company stock exchange capitalization indicators:
- issuer book value statistics:
- company liabilities and liquidity data:
Total Debt to Capital Denali Therapeutics|DNLI - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital Denali Therapeutics Inc.|DNLI - Company Cumulative Debt|Debt to Book Capitalization Ratio Denali|DNLI - Company Long-Term Indebtedness|Company Short-Term Debts Denali Therapeutics|Quick Liquidity denalitherapeutics.com
- company profitability and valuation multiples indicators:
Analysis of all company metrics:DNLI Denali Therapeutics Inc
This ratio measures the proportion of short-term liabilities within the equity structure, allowing for an assessment of liquidity risk in the event of a sharp increase in payments. An analysis of the historical ratio of short-term loans to equity for Denali Therapeutics (DNLI) confirms the company's financial stability, as the development of its non-cyclical scientific research relies on strategic partnerships, minimizing dependence on macro-environment volatility.
Who Denali Therapeutics competes with
Short-Term Debt to Capital BIIB|NBIX - Current Liabilities to Capital|Regencell Bioscience - Short-Term Debt to Equity Ratio|Short-Term Debt to Capital axsome.com AXSM|ACAD - Short-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital XENE (Xenon Pharmaceuticals Inc.)|Viking Pharma (VKTX) - Short-Term Debt to Equity|Current Liabilities to Capital Supernus Corp (SUPN)|CPRX (Catalyst Pharmaceuticals) - Short-Term Debt to Capital|Short-Term Debt to Capital Ratio HRMY (harmonybiosciences.com)|Short-Term Debt to Capital BHVN|AMLX - Current Liabilities to Capital|Short-Term Debt to Equity Trevi Pharma TRVI|PRAX: Short-Term Debt to Capital Ratio|Anavex Life Sciences - Short-Term Debt to Capital|CBLL - Short-Term Debt to Capital|Prothena Corp (PRTA) - Short-Term Debt to Equity|ALEC (Alector) - Short-Term Debt to Equity|ANNX (Annexon Inc.) - Short-Term Debt to Capital|Omeros Corp. (OMER) - Short-Term Debt to Capital Coefficient|Short-Term Debt to Equity Ratio NGNE (Neurogene Inc.)|ACIU (acimmune.com) - Ratio of Short-Term Indebtedness to Capital|Voyager Therapeutics, Inc. - Short-Term Debt to Equity Ratio|Short-Term Loans to Capital Ratio NMRA (Neumora)|Scilex Holding Co. - Short-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital TVGN (Tevogen Bio Inc.)|ACOG: Short-Term Debt to Capital|Current Liabilities to Capital cogrx.com (CGTX)|Short-Term Debt to Equity Inhibikase Therapeutics, Inc.|SAVA: Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Capital ASRT|Short-Term Debt to Capital coyatherapeutics.com (COYA)|Short-Term Debt to Equity Vistagen VTGN|OVID (Ovid Therapeutics Inc) - Current Liabilities to Equity|Acumen Pharmaceuticals, Inc. - Short-Term Debt to Capital|Current Liabilities to Capital CervoMed, Inc.|ATHE (alteritytherapeutics.com) - Short-Term Debt to Equity Ratio|Clene (CLNN) - Short-Term Debt to Capital|Short-Term Debt to Equity Ratio PEPG|JUNS (jupiterneurosciences.com) - Short-Term Loans to Capital Ratio|Short-Term Debt to Capital RLMD|Short-Term Debt to Capital Coefficient Annovis Bio Inc|Short-Term Debt to Capital GRCE (Grace Therapeutics)|AIFF - Short-Term Debt to Equity Ratio|KLTO - Short-Term Debt to Equity|Short-Term Debt to Capital Coefficient NeuroSense Therapeutics NRSN|RVPH: Short-Term Debt to Capital|Short-Term Debt to Capital Ratio MTVA|Short-Term Debt to Equity NeurAxis, Inc|Short-Term Debt to Capital Ratio HSDT (Helius Medical Technologies Inc.)|Short-Term Debt to Equity Passage Bio, Inc. (PASG)|Short-Term Debt to Equity NEUP (bionomics.com.au)|Short-Term Debt to Capital NERV (Minerva Neurosciences, Inc.)|Short-Term Debt to Capital Coefficient Athira Pharma Inc (ATHA)|ADXN - Short-Term Debt to Equity|ALZN (Alzamend Neuro, Inc.) - Short-Term Debt to Capital Ratio|CYCN: Short-Term Debt to Capital|Current Liabilities to Capital Protagenic Therapeutics, Inc. (PTIX)|Short-Term Debt to Equity Ratio KTTA|Short-Term Debt to Capital Cortigent Medical|Short-Term Debt to Equity Avenue Therapeutics, Inc (ATXI)|BCLI (BrainStorm Cell Therapeutics Inc.) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity Cara Therapeutics, Inc. CARA|chromocell.com (CHRO) - Current Liabilities to Capital|Eliem - Short-Term Debt to Capital|ITCI (Intra-Cellular Therapies) - Short-Term Debt to Capital Ratio|LBPH: Short-Term Debt to Capital|Current Liabilities to Capital Marinus Pharma (MRNS)|Short-Term Debt to Equity NKGen Biotech, Inc.|Short-Term Debt to Capital Ratio NRBO (neurobopharma.com)|Short-Term Debt to Capital SAGE|Short-Term Debt to Capital Synaptogenix Inc. (SNPX)|Short-Term Debt to Equity Trevena, Inc TRVN|Vigil Neuroscience Inc. - Short-Term Debt to Equity|Anew Medical, Inc. - Short-Term Debt to Capital|Short-Term Debt to Capital Coefficient cerevel.com CERE